Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06331598
Title A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)
Acronym IMperator
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: senior | adult
Covered Countries ESP

Facility Status City State Zip Country Details
Hospital Universitari Vall dHebron; Oncology RECRUITING Barcelona 08035 Spain Details
Hospital Universitario 12 de Octubre; Servicio de Oncologia RECRUITING Madrid 28041 Spain Details
Hospital Universitario Virgen; Servicio de Oncologia RECRUITING Sevilla 41013 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field